Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female on stable dose of IgPro20 (Hizentra) therapy.~* Women of childbearing potential must be using and agree to continue using medically approved contraception (which must be discussed with the study doctor) and must have a negative pregnancy test at screening.~* Subjects with PID, eg, with a diagnosis of common variable immunodeficiency or X-linked agammaglobulinemia, as defined by the Pan American Group for Immune Deficiency and the European Society of Immune Deficiencies.~* With infusion parameters as specified below:~Pump-Assisted Flow Rate Cohort subjects only~* Experience with pump-assisted infusions of IgPro20 at the tolerated flow rate of 25 mL/h per injection site for at least 1 month prior to Day 1.~Pump-Assisted Volume Cohort subjects only~* Total weekly IgPro20 dose of ≥ 50 mL (≥ 10 g).~* Experience with pump-assisted infusions of IgPro20 at tolerated volumes of 25 mL/injection site for at least 1 month prior to Day 1.~Manual Push Flow Rate Cohort subjects only~* Experience with frequent (2-7 times per week) infusions of IgPro20 at the tolerated flow rate of approximately 0.5 mL/min (equivalent of 25-30 mL/h) per injection site for at least 1 month prior to Day 1. The dose (volume) per injection site should not exceed 25 mL.~Exclusion Criteria:~* Ongoing serious bacterial infections at the time of screening.~* Other significant medical conditions that could increase the risk to the subject.~* Females who are pregnant, breast feeding, or planning a pregnancy during the course study.~* Participation in a study with an Investigational Medicinal Product (IMP) other than IgPro20 within three months prior to enrollment.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IgPro20 (Pump-Assisted Volume Cohort) (Type: EXPERIMENTAL): Weekly volumes per injection site of 25 mL up to 50 mL administered subcutaneously.
- IgPro20 (Pump Assisted Flow Rate Cohort) (Type: EXPERIMENTAL): Weekly flow rates per injection site of 25 mL/hour up to 100 mL/hour administered subcutaneously.
- IgPro20 (Manual Push Flow Rate Cohort) (Type: EXPERIMENTAL): Frequent (ie, 2 to 7 times per week) flow rates per injection site of 25 to 30 mL/hour up to 120 mL/hour (equivalent of approximately 0.5 mL/minute up to 2 mL/minute) administered subcutaneously.

Based on this trial design, predict the completion outcome and termination type (if applicable).